Fulvestrant and male breast cancer: A case series

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 265-

  Zagouri, F ^a   Sergentanis, T N ^b   Chrysikos, D ^b   Zografos, E ^b   Rudas, M ^a   Steger, G ^a   Zografos, G ^b   Bartsch, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FULVESTRANT; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CASE STUDY; CLINICAL ARTICLE; DRUG TOLERABILITY; HUMAN; LETTER; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84871566100     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds597     Document Type: Letter

References (5)

1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2012. Available at www.nccn.com
2. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600.
3. Masci G, Gandini C, Zuradelli M et al. Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 2011; 22: 985.
4. de la Haba Rodríguez JR, Porras Quintela I, Pulido Cortijo G et al. Fulvestrant in advanced male breast cancer. Ann Oncol 2009; 20: 1896-1897.
5. Chan CM, Martin LA, Johnston SR et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on longterm oestrogen deprivation. J Steroid Biochem Mol Biol 2002; 81: 333-341.